INTRODUCTION: Staging systems have been developed to predict survival after resection of hilar cholangiocarcinoma. Notably, they have not been validated nor compared for relative predictive ability. METHODS: Forty-two patients underwent resection of hilar cholangiocarcinoma and have been followed through a prospectively collected database. The tumors were staged using the Bismuth-Corlette, Blumgart, and American Joint Committee on Cancer (AJCC) systems, and a significant relationship with survival was sought. RESULTS: Eleven patients were treated by extrahepatic biliary resection alone, while 31 required extrahepatic biliary resections with in-continuity hepatic resections. All patients underwent adjuvant therapy. To date, 30 patients have died with a mean survival time of 30 months +/- 35.0 (SD). Twelve patients are alive with a mean survival of 90 months +/- 61.8. By regression analysis, none of the staging systems had a significant relationship with survival (Bismuth: P = .64; Blumgart: P = .66; AJCC: P = .31). CONCLUSIONS: Most patients with hilar cholangiocarcinoma require in-continuity hepatic resections. Survival after resection promotes an aggressive approach, with cure in as many as 30%. Staging systems should not impact the decision to operate or postoperative management, as all tumors should be aggressively resected and all patients should receive adjuvant treatment.
INTRODUCTION: Staging systems have been developed to predict survival after resection of hilar cholangiocarcinoma. Notably, they have not been validated nor compared for relative predictive ability. METHODS: Forty-two patients underwent resection of hilar cholangiocarcinoma and have been followed through a prospectively collected database. The tumors were staged using the Bismuth-Corlette, Blumgart, and American Joint Committee on Cancer (AJCC) systems, and a significant relationship with survival was sought. RESULTS: Eleven patients were treated by extrahepatic biliary resection alone, while 31 required extrahepatic biliary resections with in-continuity hepatic resections. All patients underwent adjuvant therapy. To date, 30 patients have died with a mean survival time of 30 months +/- 35.0 (SD). Twelve patients are alive with a mean survival of 90 months +/- 61.8. By regression analysis, none of the staging systems had a significant relationship with survival (Bismuth: P = .64; Blumgart: P = .66; AJCC: P = .31). CONCLUSIONS: Most patients with hilar cholangiocarcinoma require in-continuity hepatic resections. Survival after resection promotes an aggressive approach, with cure in as many as 30%. Staging systems should not impact the decision to operate or postoperative management, as all tumors should be aggressively resected and all patients should receive adjuvant treatment.
Authors: Roongruedee Chaiteerakij; William S Harmsen; Carlos Romero Marrero; Mohammed M Aboelsoud; Albert Ndzengue; Joseph Kaiya; Terry M Therneau; William Sanchez; Gregory J Gores; Lewis R Roberts Journal: Am J Gastroenterol Date: 2014-11-11 Impact factor: 10.864
Authors: Wolf-Rudiger Matull; Dipok K Dhar; Lakshmana Ayaru; Neomal S Sandanayake; Michael H Chapman; Aruna Dias; John Bridgewater; George J M Webster; Jin J Bong; Brian R Davidson; Stephen P Pereira Journal: Liver Int Date: 2010-09-16 Impact factor: 5.828
Authors: Matthew J Weiss; David Cosgrove; Joseph M Herman; Neda Rastegar; Ihab Kamel; Timothy M Pawlik Journal: Langenbecks Arch Surg Date: 2014-06-25 Impact factor: 3.445
Authors: Kyueng-Whan Min; Dong-Hoon Kim; Byoung Kwan Son; Eun-Kyung Kim; Sang Bong Ahn; Seong Hwan Kim; Yun Ju Jo; Young Sook Park; Jinwon Seo; Young Ha Oh; Sukjoong Oh; Ho Young Kim; Mi Jung Kwon; Soo Kee Min; Hye-Rim Park; Ji-Young Choe; Jang Yong Jeon; Hong Il Ha; Jung Woo Lee Journal: World J Surg Date: 2017-01 Impact factor: 3.352